ACE2 News and Research

RSS

Alkaloids show potential as treatments for COVID-19

To further study these organic compounds, researchers from Kermanshah University of Medical Sciences, Iran, and Universidad de Santiago de Chile, Chile, reviewed the role of alkaloids as a potential antiviral, specifically against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They presented the chemistry, plant sources, and antiviral effects of alkaloids and their anti-SARS-CoV-2 effect.

15 Jun 2021

Immune memory responses differ between SARS-CoV-2 and influenza A

Researchers in Canada have shown that the long-lasting immunity that develops following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by different T cell responses than those observed for influenza A virus-specific immune memory.

14 Jun 2021

Intranasal monoclonal SARS-CoV-2 antibody therapy shows promise in preclinical trials

A new study, released as a preprint on the bioRxiv* server, presents a new monoclonal antibody (MAb) called DZIF-10c that powerfully neutralizes SARS-CoV-2, including the current variants of concern (VOCs). With high bioavailability in the lungs and wide distribution in the body, the antibody was able to prevent SARS-CoV-2 infection in mice after intranasal administration.

14 Jun 2021

Fatty acid binding site on SARS-CoV-2 spike triggers spike monomer crosstalk that is key to infectivity

A new study, released as a preprint on the bioRxiv* server, examines the role played by a fatty acid called linoleic acid (LA) that attaches at a binding site near the receptor-binding domain (RBD) of the spike protein. The spike exists as a homotrimer in open or closed conformations. In the former, at least one RBD points upwards.

14 Jun 2021

Forkhead box O's potential therapeutic use in the treatment of COVID-19

In a recent study, Indian researchers from the Department of Biochemistry, University of Delhi, reviewed a possible vital coalition of FoxOs - the Forkhead Box O subfamily of protein transcription factors, with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the etiological agent of COVID-19 (coronavirus disease).

13 Jun 2021

What makes the elderly more susceptible to SARS-CoV-2 infection?

Why is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 (coronavirus disease 2019), biased towards infecting the aged population? A recently published study by Italian scientists linked aging, DNA damage, telomere shortening, and increased levels of angiotensin-converting enzyme 2 (ACE2) to this relationship.

13 Jun 2021

Role of traditional medicine against SARS-CoV-2

A group of researchers at Kannur University reviewed selected papers and in silico work on potential drug leads that could be used to manage COVID-19.

13 Jun 2021

Humoral innate pattern recognition molecules against SARS-CoV-2

In a paper recently uploaded to the preprint server medRxiv by Garlanda et al. (June 8th, 2021), humoral pattern recognition molecules are explored for affinity towards SARS-CoV-2, contributing to unraveling the role of these molecules in COVID-19 disease progression.

13 Jun 2021

An analysis links COVID-19 to brain microvascular injury and inflammation

The ongoing COVID-19 pandemic is caused by the severe acute respiratory syndrome-2 (SARS-CoV-2), an RNA virus that belongs to the family Coronaviridae. According to research, coronavirus disease 2019 (COVID-19) patients often suffer from neurological disorders like strokes, lost taste or smell, memory loss, confusion, and delirium.

13 Jun 2021

Statins associated with reduced COVID-19 mortality and decreased need for ventilator support

Statins are medications widely used in the management of cardiovascular diseases and metabolic syndrome. Statins help lower serum lipids by blocking HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase), the rate-limiting enzyme of cholesterol biosynthesis.

11 Jun 2021

Nanobodies from nanomice and llamas show potent neutralizing activity against SARS-CoV-2 variants

While several COVID-19 vaccines have been approved to date, the constant evolution of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) receptor-binding domain (RBD) has challenged the efficacy of these vaccines.

11 Jun 2021

Shark vNAR antibodies inhibit SARS-CoV-2 variants in vitro

Researchers in the UK and Austria have identified a novel class of antibodies that is highly effective at neutralizing the original strain of severe acute respiratory syndrome (SARS-CoV-2) and maintaining blocking activity against certain viral variants that have emerged.

10 Jun 2021

Compound may block COVID-19 virus from entering lung cells, study reports

Research conducted at LSU Health New Orleans Neuroscience Center of Excellence reports that Elovanoids, bioactive chemical messengers made from omega-3 very-long-chain polyunsaturated fatty acids discovered by the Bazan lab in 2017, may block the virus that causes COVID-19 from entering cells and protect the air cells (alveoli) of the lung.

10 Jun 2021

Bovine-derived polyclonal antibodies exhibit high efficacy in neutralizing SARS-CoV-2 variants

A team of scientists in Estonia has recently evaluated the therapeutic/prophylactic efficacy of anti-SARS-CoV-2 polyclonal antibodies derived from the colostrum of immunized cows.

10 Jun 2021

DNA on-off switches for SARS-CoV-2 host receptor as potential therapeutic targets

Researchers in the United States and Canada have identified DNA on/off “switches” within the angiotensin-converting enzyme 2 (ACE2) gene that may control the expression of this host cell receptor before, during and after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

9 Jun 2021

Smoking and vaping increase ACE2 levels and virus spike binding in airway epithelium

A new bioRxiv preprint attempts to make some sense of why certain people experience more severe forms of COVID-19 as compared to others by pointing to the increase in virus binding that occurs in the presence of smoking or vaping.

9 Jun 2021

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

In a recently published article in the journal Frontiers in Immunology, scientists have reviewed the existing literature on antiviral and anti-inflammatory efficacy of resveratrol-based inhaled formulations in preventing SARS-CoV-2 infection and reducing COVID-19 severity.

9 Jun 2021

How SARS-CoV-2 variant B.1.1.7 adapted to evade innate immunity

Researchers in the United States and the UK have conducted a study showing how the B.1.1.7 (Alpha) lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) adapted to suppress host innate immune responses in lung epithelial cells.

8 Jun 2021

Researchers identify a novel host-directed therapeutic approach to COVID-19

Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).

8 Jun 2021

Cell-to-cell contact helps in spreading SARS-CoV-2, finds study

People aren’t the only ones who should be social distancing — new research shows our cells need to as well. Researchers from Ohio State University in Columbus, Ohio, USA, used in-culture techniques to confirm SARS-CoV-2 transmission via cell-to-cell contact.

8 Jun 2021

ACE2 News and Research

Alkaloids show potential as treatments for COVID-19

Immune memory responses differ between SARS-CoV-2 and influenza A

Intranasal monoclonal SARS-CoV-2 antibody therapy shows promise in preclinical trials

Fatty acid binding site on SARS-CoV-2 spike triggers spike monomer crosstalk that is key to infectivity

Forkhead box O's potential therapeutic use in the treatment of COVID-19

What makes the elderly more susceptible to SARS-CoV-2 infection?

Role of traditional medicine against SARS-CoV-2

Humoral innate pattern recognition molecules against SARS-CoV-2

An analysis links COVID-19 to brain microvascular injury and inflammation

Statins associated with reduced COVID-19 mortality and decreased need for ventilator support

Nanobodies from nanomice and llamas show potent neutralizing activity against SARS-CoV-2 variants

Shark vNAR antibodies inhibit SARS-CoV-2 variants in vitro

Compound may block COVID-19 virus from entering lung cells, study reports

Bovine-derived polyclonal antibodies exhibit high efficacy in neutralizing SARS-CoV-2 variants

DNA on-off switches for SARS-CoV-2 host receptor as potential therapeutic targets

Smoking and vaping increase ACE2 levels and virus spike binding in airway epithelium

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

How SARS-CoV-2 variant B.1.1.7 adapted to evade innate immunity

Researchers identify a novel host-directed therapeutic approach to COVID-19

Cell-to-cell contact helps in spreading SARS-CoV-2, finds study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News